Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01369212
Other study ID # DK082864 HBRN Immune Active
Secondary ID U01DK082864U01DK
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2012
Est. completion date March 8, 2021

Study information

Verified date April 2023
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial compares the efficacy of peginterferon plus tenofovir for 24 weeks followed by monotherapy with tenofovir for a further 3.5 years to the efficacy of tenofovir alone given for 4 years in patients with chronic hepatitis B. The primary measure of outcome will be HBsAg loss in serum at 48 weeks after stopping all antiviral therapy (sustained off-treatment response).


Description:

The objective of this study is to compare the long-term efficacy of treatment with combination therapy with peginterferon plus tenofovir versus tenofovir monotherapy in the treatment of chronic hepatitis B. This is a randomized (1:1) parallel group design trial comparing (i) tenofovir disoproxil fumarate (TDF) 300 mg daily for 192 weeks (4 years) and (ii) peginterferon alfa-2a 180 µg weekly for 24 weeks plus Tenofovir DF 300 mg daily for 192 weeks (4 years). Enrolled participants will be stratified by HBeAg status (positive/negative), genotype (A vs. all others) and cirrhosis (present vs. absent). After 192 weeks of treatment, participants meeting criteria for treatment discontinuation will stop treatment and be followed for 48 weeks (total duration of treatment and follow up is 240 weeks). Emtricitabine/tenofovir coformulated as Truvada, approved for treatment of HIV but not for treatment of hepatitis B virus (HBV) infection, will be offered to patients with primary nonresponse, partial virological response or confirmed virologic breakthrough.


Other known NCT identifiers
  • NCT01821794

Recruitment information / eligibility

Status Completed
Enrollment 201
Est. completion date March 8, 2021
Est. primary completion date March 8, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Participant is enrolled in the HBRN Cohort Study (NCT01263587) or completed the necessary components of the cohort baseline evaluation by the end of the baseline visit for this study - 18 years or older - Chronic hepatitis B infection as evidenced by at least one of the following: 1. HBsAg positive result within 8 weeks prior to randomization and another time at least 24 weeks prior to randomization with no HBsAg negative result in between. 2. HBsAg positive within 8 weeks prior to randomization and HBV DNA =1000 IU/mL on 2 occasions at least 24 weeks apart (can include result from screening visit within 8 weeks of randomization) - Hepatitis B e antigen positive or negative - Serum HBV DNA =1000 IU/mL on 2 occasions at least 4 weeks apart within the 32 weeks prior to randomization (can include result from screening visit within 8 weeks of randomization) - At least 2 elevated serum alanine aminotransferase (ALT) levels (> 30 U/L for males, >20 U/L for females) 4 weeks apart, and no more than 32 weeks apart, with the second being within 8 weeks of randomization - Compensated liver disease - No evidence of hepatocellular carcinoma (HCC) - Liver biopsy done that shows findings consistent with chronic hepatitis B with histology activity index (HAI) =3 (necroinflammatory component only) or Ishak fibrosis score =1 or both, as assessed by the local study pathologist on review of a liver biopsy done within 144 weeks of randomization - Females of child bearing potential must agree to use an adequate method of contraception throughout the study and must have a negative pregnancy test immediately prior to the start of treatment Exclusion criteria: - Serum ALT =450 U/L for males and =300 U/L for females - Treatment with interferon or nucleos(t)ide analogues for hepatitis B within 48 weeks of randomization - More than 48 weeks of therapy with nucleos(t)ide analogues for hepatitis B at any time in the past - History of hepatic decompensation including but not limited to ascites, variceal bleeding, or hepatic encephalopathy - Known allergy or intolerance to any of the study medications - Females who are pregnant or breastfeeding - Previous organ transplantation including engrafted bone marrow transplant - Any other concomitant liver disease, including hemochromatosis, hepatitis C or D; Participants with severe steatohepatitis will be excluded (participants with non-alcoholic fatty liver disease [NAFLD] with steatosis only and/or mild to moderate steatohepatitis are acceptable) - Positive anti-HIV - Renal insufficiency with calculated (by Modification of Diet in Renal Disease (MDRD) method) creatinine clearance <60 mL/min within 8 weeks prior to randomization - Platelet count <90,000 /mm3, hemoglobin <13 g/dL (males) or <12 g/dL (females), absolute neutrophil count <1500 /mm^3 (<1000/mm^3 for African-Americans) within 8 weeks prior to randomization - History of active alcohol or drug abuse within 48 weeks of screening. - Pre-existing psychiatric condition(s), including but not limited to: Current moderate or severe depression as determined by the study physician, history of depression requiring hospitalization within past 10 years, history of suicidal or homicidal attempt within the past 10 years, or history of severe psychiatric disorders including but not limited to schizophrenia, psychosis, bipolar disorder - History of immune-mediated disease, or cerebrovascular, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, poorly controlled diabetes or uncontrolled seizure disorder - Any medical condition that would be predicted to be exacerbated by therapy or that would limit study participation - Any medical condition requiring or likely to require chronic systemic administration of corticosteroids or other immunosuppressive medications during the course of this study - Evidence of active or suspected malignancy, or a history of malignancy within the last 144 weeks (except adequately treated carcinoma in situ or basal cell carcinoma of the skin) - Need for ongoing use of any antivirals with activity against HBV during the course of the study - Any other condition that in the opinion of the investigator would make the participant unsuitable for enrollment or could interfere with the participant participating in and completing the study. - Participation in any other clinical trial involving investigational drugs within 30 days of randomization or intention to participate in another clinical trial during this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tenofovir
300 mg daily for 192 weeks (4 years)
Peginterferon-alfa 2a and tenofovir
A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).

Locations

Country Name City State
Canada University of Toronto-Toronto Western Hospital Toronto Ontario
United States University of Michigan Health System Ann Arbor Michigan
United States NIH Clinical Center Bethesda Maryland
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States University of North Carolina Chapel Hill North Carolina
United States Baylor University Medical Center Dallas Texas
United States University of Texas Southwestern Dallas Texas
United States Duke University Medical Center Durham North Carolina
United States Queen's Medical Center Honolulu Hawaii
United States Cedars Sinai Medical Center Los Angeles California
United States University of California Los Angeles Los Angeles California
United States University of Minnesota Plymouth Minnesota
United States Virginia Commonwealth University Richmond Virginia
United States Mayo Clinic Rochester Minnesota
United States Saint Louis University Saint Louis Missouri
United States Washington University Saint Louis Missouri
United States California Pacific Medical Center San Francisco California
United States University of California San Francisco San Francisco California
United States University of Washington Medical Center Seattle Washington
United States Virginia Mason Medical Center Seattle Washington

Sponsors (3)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Center for Research Resources (NCRR), University of Pittsburgh

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Participants With Hepatitis B Surface Antigen (HBsAg) Loss by Week 240 Estimated percent of participants who became HBsAg negative by week 240 from randomization Week 240
Secondary Cumulative Percent of Participants With HBsAg Loss at Week 192 Cumulative percentage of participants with HBsAg loss at week 192 estimated using Kaplan-Meier method Week 192
Secondary Number of Participants With Serious Adverse Events Number of participants with at least one serious adverse event between randomization and week 240 Up to 240 weeks
Secondary Number of Participants With Adverse Events Number of participants with at least one adverse event between randomization and week 240 up to 240 weeks
Secondary Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 192 Number of participants who became Hepatitis B e antigen (HBeAg) negative at week 192 among HBeAg positive participants at randomization (baseline) week 192
Secondary Number of Participants With HBeAg Loss at Week 240 Number of participants who became HBeAg negative at week 240 among HBeAg positive participants at baseline week 240
Secondary Number of Participants With HBsAg Seroconversion at Week 192 Number of participants who became with HBsAg negative and developed anti-HBs at week 192 week 192
Secondary Number of Participants With HBsAg Seroconversion at Week 240 Number of participants who became HBsAg negative and developed anti-HBs at week 240 week 240
Secondary Number of Participants With HBeAg Seroconversion at Week 192 Number of participants who became HBeAg negative and developed anti-HBe at week 192 among HBeAg positive participants at baseline week 192
Secondary Number of Participants With HBeAg Seroconversion at Week 240 Number of participants who became HBeAg negative and developed anti-HBe at week 240 among HBeAg positive participants at baseline week 240
Secondary Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 192 Number of participants with normal alanine transaminase (ALT) levels at week 192 (Normal ALT for males =30 U/L, for females =20 U/L) week 192
Secondary Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 240 Number of participants with normal alanine transaminase (ALT) levels [males =30 U/L, for females =20 U/L] at week 240 week 240
Secondary Number of Participants With HBV DNA<1000 IU/mL at Week 192 Number of participants with HBV DNA <1000 IU/mL at week 192 week 192
Secondary Number of Participants With HBV DNA<1000 IU/mL at Week 240 Number of participants with HBV DNA <1000 IU/mL at week 240 week 240
Secondary Number of Participants With HBV DNA<20 IU/mL at Week 192 Number of participants with HBV DNA<20 IU/mL at week 192 week 192
Secondary Number of Participants With HBV DNA<20 IU/mL at Week 240 Number of participants with HBV DNA<20 IU/mL at week 240 week 240
Secondary Absence of Detectable Antiviral Drug-Resistant HBV Mutations at Week 192 Absence of detectable antiviral drug-resistant HBV mutations at Week 192 week 192
Secondary Cumulative Percent of Participants With HBsAg Loss at Week 240 Cumulative percent of participants with HBsAg loss at week 240 estimated using Kaplan-Meier method Week 240
Secondary Number of Participants With Alanine Transaminase(ALT) Levels <= 38 U/L for Males and <=25 for Females at Week 192 Number of participants with alanine transaminase(ALT) levels <= 38 U/L for males and <=25 for females at week 192. The cut-offs 38 and 25 are approximately 1.25 times the upper limit of normal (30 U/L for males and 20 U/L for females) respectively. week 192
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A

External Links